The clinical role of combined circulating complement C1q and AIP for CAD with LDL-C level below 1.8mmol/L.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X (Electronic) Linking ISSN: 1476511X NLM ISO Abbreviation: Lipids Health Dis Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2002-

Complement C1q*/metabolism ; Coronary Artery Disease*/blood ; Cholesterol, LDL*/blood; Humans ; Male ; Female ; Middle Aged ; Aged ; Coronary Angiography ; Biomarkers/blood ; ROC Curve ; Logistic Models ; Atherosclerosis/blood ; Risk Factors

Background: In the past few years, circulating complement C1q involvement in atherosclerosis has garnered growing research interest in addition to the emerging recognition of the novel lipid marker named atherogenic index of plasma (AIP). Nevertheless, among patients experiencing low-density lipoprotein cholesterol (LDL-C) levels less than 1.8mmol/L, the interplay between C1q combined with the AIP for coronary artery disease (CAD) is ambiguous.
Methods: Patients were stratified into a non-CAD and CAD group according to their coronary angiography. The association between C1q in conjunction with the AIP and CAD was explored using restricted cubic spline analyses and logistic regression models. To assess how it predicted, a receiver operating characteristic analysis was undertaken.
Results: A total of 7270 patients comprised 1476 non-CAD patients and 5794 patients diagnosed with CAD were analyzed. A comparison of the two groups showed that the C1q levels were notably higher compared to the CAD group, while AIP exhibited an inverse trend. Across quartiles of C1q, the AIP demonstrated a decline with increasing C1q levels, and significant differences were observed between the groups. A correlation analysis underscored a notable negative correlation between the two variables. Univariate and multivariate logistic regression analyses revealed significant associations between CAD and the C1q quartile groups/AIP. Furthermore, compared with the Q4 group, a decrease in the C1q levels corresponded to an escalation in CAD risk, with the odds ratio rising from 1.661 to 2.314.
Conclusions: In conclusion, there appears to be a notable positive correlation between the combination of C1q with the AIP and CAD.
(© 2024. The Author(s).)

Immunity. 2023 Aug 8;56(8):1809-1824.e10. (PMID: 37499656)
Cardiovasc Diabetol. 2023 Jun 29;22(1):157. (PMID: 37386500)
BMC Endocr Disord. 2023 Aug 31;23(1):187. (PMID: 37653411)
J Atheroscler Thromb. 2022 Feb 1;29(2):268-281. (PMID: 33536384)
Peptides. 2023 May;163:170980. (PMID: 36842629)
Acta Pharmacol Sin. 2023 Apr;44(4):710-725. (PMID: 36207402)
Front Immunol. 2022 Sep 30;13:969984. (PMID: 36248871)
Nature. 2021 Apr;592(7855):524-533. (PMID: 33883728)
Int J Mol Sci. 2022 Sep 14;23(18):. (PMID: 36142647)
Angiology. 2022 Nov-Dec;73(10):936-945. (PMID: 35191328)
J Geriatr Cardiol. 2022 Dec 28;19(12):949-959. (PMID: 36632200)
Mol Immunol. 2020 Apr;120:130-135. (PMID: 32120180)
Atherosclerosis. 2016 Oct;253:38-46. (PMID: 27573737)
PLoS One. 2022 Jan 27;17(1):e0262413. (PMID: 35085285)
Lipids Health Dis. 2020 Feb 24;19(1):27. (PMID: 32093690)
Oncol Lett. 2021 Oct;22(4):723. (PMID: 34429763)
Eur Heart J. 2016 Jun 07;37(22):1762-71. (PMID: 26705391)
EBioMedicine. 2020 Oct;60:102985. (PMID: 32927275)
Clin Biochem. 2001 Oct;34(7):583-8. (PMID: 11738396)
J Cell Mol Med. 2023 May;27(9):1168-1178. (PMID: 37002701)
Lipids Health Dis. 2020 Mar 16;19(1):44. (PMID: 32178671)
Front Cardiovasc Med. 2021 Apr 29;8:618173. (PMID: 33996933)
Am J Cardiol. 2018 Jul 1;122(1):33-38. (PMID: 29703440)
Front Immunol. 2023 Dec 21;14:1289223. (PMID: 38179058)
Clin Biochem. 2021 Jul;93:50-58. (PMID: 33861985)
Arterioscler Thromb Vasc Biol. 2018 May;38(5):1242-1244. (PMID: 29567681)
Angiology. 2021 Nov;72(10):934-941. (PMID: 33949211)
Immunol Res. 2016 Feb;64(1):1-13. (PMID: 26091721)
Cardiovasc Diabetol. 2023 Jun 26;22(1):150. (PMID: 37365588)
IUBMB Life. 2020 Aug;72(8):1698-1704. (PMID: 32311832)
Int Immunopharmacol. 2019 Dec;77:105934. (PMID: 31727560)
Mol Med. 2022 Dec 21;28(1):160. (PMID: 36544112)
Eur Heart J. 2023 Sep 14;44(35):3307-3308. (PMID: 37563238)
Immunity. 2022 Nov 8;55(11):1993-2005. (PMID: 36351374)
Diabetes Metab Res Rev. 2021 Feb;37(2):e3367. (PMID: 32558162)
Curr Atheroscler Rep. 2020 May 28;22(6):22. (PMID: 32468164)
J Autoimmun. 2023 May;137:102979. (PMID: 36535812)

2022YFC3602500 National Key Research and Development Program of China

Keywords: Atherogenic index of plasma; C1q; Coronary artery disease; Diabetes; LDL-C < 1.8mmol/L

80295-33-6 (Complement C1q)
0 (Cholesterol, LDL)
0 (Biomarkers)

Date Created: 20240504 Date Completed: 20240504 Latest Revision: 20240524

20240525

PMC11070092

10.1186/s12944-024-02127-8

38704561